Sudarshan Pharma Industries Share Price Today

Sudarshan Pharma shares to list on NSE Main Board from Oct 27

Sudarshan Pharma Industries Ltd shares list on NSE Main Board from October 27, 2026. Migration occurs from BSE SME Platform to Capital Market Segment. Total listed equity shares stand at 254,470,600 with face value ₹1 each. Approximately 50% of shares remain locked in until December 2027.

Sudarshan Pharma terminates proposal to acquire stake in US biotech firm

Sudarshan Pharma Industries terminated its proposal to acquire 9.50% equity in Med Therapy Biotechnology Inc., USA. Promoters Hemal Mehta and Sachin Mehta also cancelled their respective 1.50% stake acquisition plans. The termination was disclosed to the BSE under Regulation 30 of SEBI LODR Regulations, 2015.

Sudarshan Pharma exits Ishwari Healthcare after ₹1.40 crore stake sale

Sudarshan Pharma sold 2,09,100 equity shares in Ishwari Healthcare. Total consideration received was ₹1.40 crore. Shareholding in Ishwari dropped from 51% to nil. Ishwari Healthcare ceased to be a subsidiary post-transaction.

Sudarshan Pharma AGM resolutions pass with 100% votes in favour

All AGM resolutions passed with 100% votes in favour. 77,633,810 shares voted in support of both agenda items. Remote e-voting period ran from September 19 to September 21, 2026. Promoters held 51.19% of outstanding shares during voting.

Sudarshan Pharma says Med Therapy stake deal is under due diligence

Sudarshan Pharma Industries proposes acquiring 9.50% stake in Med Therapy Biotechnology Inc. Deal is currently under due diligence pending Med Therapy board resolution. Promoters Hemal Mehta and Sachin Mehta seek 1.50% stake each in same entity. Company cites Regulation 30 of SEBI LODR Regulations for this disclosure. Further updates expected once due diligence and approvals are complete.

Sudarshan Pharma promoter releases pledge on 2 lakh shares

Promoter Mr. Hemal Mehta released pledge on 2,00,000 equity shares. Pledge release occurred on August 6, 2026. Original encumbrance was for personal loans taken by the promoter. Disclosure filed with BSE on September 9, 2026. Mehta holds 26.60% stake (6,40,21,020 shares) in the company.